Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSE: Rontalizumab in SLE
NCT00962832Phase 2Completed
- Sponsor
- Genentech
- Start
- Sep 2009
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of rontalizumab in systemic lupus erythematosus (SLE), sponsored by Genentech. Started Sep 2009; status: completed.
02
Drugs
rontalizumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00962832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962832.